ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

repaglinide

Also written as “Repaglinide”, “repaglinide and metformin combination tablet” and “Repaglinide/Metformin combination, Repaglinide, Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Overweight · Gastrointestinal Stromal Tumors · Gout, led by 4 companies.

Drug pageRepaglinide: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 200718 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only130 open or runningphase 4since Jun 25, 2007Jun 25, 2007none ahead
Eli Lilly30 open or runningphase 1since Jul 20, 2022Jul 20, 2022none ahead
Dalim BioTechits history only10 open or runningphase 1since Jan 29, 2013Jan 29, 2013none ahead
Merckits history only10 open or runningphase 4since Oct 16, 2012Oct 16, 2012none ahead

Also a collaborator on its studies: Basilea Pharmaceutica International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2022First study: phase 1 study in HealthyFirst studyNCT05469113 · 16 enrolled · United States
  2. Nov 30, 2023Phase 1 study in HealthyNCT06165146 · 16 enrolled · United States
  3. Jul 10, 2024Phase 1 study in HealthyNCT06503679 · 49 enrolled · United States

TargetBeta

“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mitiglinideruleKissei Pharmaceuticalphase 49

Studies

All 3 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06503679Healthy · United States1CompletedDec 31, 202449
NCT06165146Healthy · United States1CompletedDec 30, 202016
NCT05469113Healthy · United States1CompletedMar 5, 201916

How it is read

Names in the registry

  • “Repaglinide”, 15 entries
  • “repaglinide”, 13 entries
  • “repaglinide and metformin combination tablet”, 2 entries
  • “Repaglinide/Metformin combination, Repaglinide, Metformin”, 2 entries
  • “repaglinide 0.5 mg tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.